2/25/2023 0 Comments 8 c yfcnegf.obvHowever, it is unknown whether an SOF-based regimen can rescue patients with treatment failure by the combination therapy with OBV/PTV/r+RBV or GLE/PIB to date. Currently, three interferon (IFN)-free DAA-based therapies as mentioned above are available, and SOF/ledipasvir (LDV) combination therapy has just become available for HCV-infected patients with genotype 2 in Japan.Īn SVR to the combination therapies of OBV/PTV/r+RBV and GLE/PIB in HCV-infected patients with genotype 2 who showed virologic failure with the SOF/RBV regimen was achieved. These direct-acting antiviral agent (DAA)-based therapies have a relatively favorable safety profile.Īlthough the efficacy of DAA-based therapy is quite high, we have recently experienced a certain percentage of patients with on-treatment virologic failure during treatment and virologic relapse during post-treatment for DAA-based therapy. The combination therapy of GLE/PIB for HCV-infected patients with genotype 2 shows SVR12 rates of 97.8% and 100% for patients with chronic hepatitis and those with liver cirrhosis, respectively. The sustained virological responses at 12 wk after treatment (SVR12) for HCV-infected patients with genotype 2 are 97% and 91.5% for the 12-wk SOF/RBV regimen and 16-wk OBV/PTV/r+RBV regimen, respectively. 5.4) of the JSH guideline, and this regimen was completely replaced by the combination therapy of GLE/PIB in the most recent version (ver. Ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r+RBV) was the 1 st-choice therapeutic option for HCV-infected patients with genotype 2 in Japan according to the previous version (ver. 6.2) of the Japan Society of Hepatology (JSH) guideline for the management of HCV infection. The combination therapies with sofosbuvir/ribavirin (SOF/RBV) and gle-caprevir/pibrentasvir (GLE/PIB) are the 1 st-choice therapeutic options for hepatitis C virus (HCV)-infected patients with genotype 2 in Japan according to the most recent version (ver.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |